Fast Fact Product Reviews

One of our products – isophosphoramide mustard (IPM) – that was licensed to ZIOPHARM Oncology, Inc. – now known as ‘Palifosfamide’ is moving nicely in Phase III trials. DEKK-TEC was awarded a US patent 7,678,778 for drug composition of matter and the concept.

A recent presentation, which received a ‘PICASSO’ award, can be viewed by clicking here. We are keeping our fingers crossed that the product continues to survive the ‘test of trials’!

The DM-CHOC-PEN project (5 R43 CA132257-2) continues to enroll patients (@ Tulane University Medical Center, New Orleans, LA) with advanced cancer in a Phase I trial (IND 68,876). A new formulation (prepared at DEKK-TEC’s new GMP facility in NOLA) with extended product stability is in use. No SLTs have been identified to date.

An abstract entitled “Interaction of 4-Demethyl-4-cholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) with Melanoma Melanin Metabolism and Cell Death” will be presented @ the Fall 2011 EORTC-NCI-ASCO meeting in Brussels. This describes a new role for DM-CHOC-PEN in melanoma.

Hydroperoxyifosfamide (HOOI) (R44 CA 094566-03 – closed) remains active (stability studies continue) and the pre-IND preparation has been completed.

We are very excited to begin the new Phase II SBIR grant (3 R44 CA125871 – Dr. Patti Weber, Program Director) on BACPT-DP (a new type camptothecin) to document pre-clinical toxicity (in collaboration with Duke Cancer Center) and prepare an IND. The drug demonstrated very impressive activity in human pancreas cancer xenograft studies (more active than gemcitabine), thus the continued interest.

DEKK-TEC News

Fast Fact Product Reviews

One of our products – isophosphoramide mustard (IPM) – that was licensed to ZIOPHARM Oncology, Inc. – now known as ‘Palifosfamide’ is moving nicely in Phase III trials. DEKK-TEC was awarded a US patent 7,678,778 for drug composition of matter and the concept. A recent presentation, which received a ‘PICASSO’ award, can be viewed by [...]

read more >>